Silexion Therapeutics (SLXN) Preferred Stock Liabilities (2023 - 2024)
Silexion Therapeutics (SLXN) posted quarterly Preferred Stock Liabilities of $18.4 million for Q2 2024, up 22.27% quarter-over-quarter from $15.1 million in Q4 2023.
Silexion Therapeutics (SLXN) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Silexion Therapeutics' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $18.4 million for Q2 2024.
- In Q2 2024, Preferred Stock Liabilities changed N/A year-over-year to $18.4 million; the TTM figure through Jun 2024 stood at $18.4 million (changed N/A YoY), while the FY2023 annual figure was $15.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2024 stood at $18.4 million, up from $15.1 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $18.4 million in Q2 2024, with the low at $15.1 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Silexion Therapeutics | 266,692.97 | -1.96 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 18.41 Mn |
| Dec 31, 2023 | 15.06 Mn |